Danone further invests in gut health and next-generation biotic research with the acquisition of The Akkermansia Company
Rhea-AI Summary
Danone (OTC:DANOY) has announced the acquisition of The Akkermansia Company (TAC), a Belgian biotic specialist with nearly 20 years of expertise. TAC is known for its groundbreaking 2004 discovery of Akkermansia muciniphila MucT™, a biotic strain clinically proven to strengthen gut barriers, reduce inflammation, and combat metabolic disorders including obesity, diabetes, and cardiovascular disease.
This strategic acquisition aligns with Danone's Renew strategy, emphasizing scientific innovation and responding to growing consumer demand for health-focused products. The company, which generated €27.4 billion in sales in 2024, operates across three health-focused categories: Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition, with products available in over 120 markets globally.
Positive
- Strategic expansion into gut health research and next-generation biotics
- Acquisition adds clinically proven biotic strain with multiple health benefits
- Aligns with growing consumer demand for health-focused products
- Strengthens Danone's scientific innovation capabilities
Negative
- Financial terms of the acquisition not disclosed
- Integration costs and timeline uncertainties
- Potential regulatory and commercialization challenges for new biotic products
News Market Reaction
On the day this news was published, DANOY declined 2.59%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Press release – Paris, June 25, 2025, at 18:00 CEST
Danone further invests in gut health and next-generation biotic research with the acquisition of The Akkermansia Company
Danone today announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics.
In 2004, using state-of-the-art technology, scientists at TAC discovered and developed a biotic strain, Akkermansia muciniphila MucT™. They clinically demonstrated its power to reinforce the gut barrier, reduce inflammation, and counteract metabolic disorders such as obesity, diabetes, and cardiovascular disease.
Expanding deeper into gut health is a key facet of Danone’s Renew strategy, as it doubles down on science and innovation, and as consumer interest in healthy products continues to rise.
About Danone (www.danone.com)
Danone is a leading global food and beverage company operating in three health-focused, fast-growing and on-trend Categories: Essential Dairy & Plant-Based products, Waters and Specialized Nutrition. With a long-standing mission of bringing health through food to as many people as possible, Danone aims to inspire healthier and more sustainable eating and drinking practices while committing to achieve measurable nutritional, social, societal and environment impact. Danone has defined its Renew strategy to restore growth, competitiveness, and value creation for the long-term. With over 90,000 employees, and products sold in over 120 markets, Danone generated
o o O o o
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. Generally, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology or by using future dates. Forward-looking statements in this press release include but are not limited to predictions of future activities, operations, direction, performance and results of Danone. These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of risks and uncertainties, please refer to the “Risk Factor” section of Danone’s Universal Registration Document (the current version of which is available at www.danone.com).
Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell or a solicitation of an offer to buy Danone securities.
Attachment
FAQ
What company did Danone (DANOY) acquire in June 2025?
What is the significance of Akkermansia muciniphila MucT™?
How does this acquisition align with Danone's strategy?
What were Danone's sales figures for 2024?
What are Danone's main business categories?
